Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Patient Advocacy Toolkit: Key Messages

Concentrate on certain key message to get your ideas across

Inequalities in Rare Cancers

RCE-microscope
  • Five-year relative survival rates are worse for rare cancers in adults (47%) than for common cancers (65%)
  • Survival rates differ significantly across Europe (gaps between Northern/Western Europe and Eastern Europe)
  • Patient access to new cancer drugs is not equitable across Europe

Diagnosis

  • Rare cancers are often misdiagnosed, leading to late or inadequate treatment
  • Rare cancer diagnostics require expert opinion
  • Need for referral (second, reimbursed, opinion)
  • Experts may not be available in the country where the patient lives
  • Need for cross-border referral
  • Experts and reference centres are poorly known to patients and doctors

Treatment

  • Few therapeutic options
  • Treatment based on low level of evidence
  • Frequent "off label" use of drugs
  • Patient referral is sub-optimal (long delays)
  • Biological material may not be readily available
  • Quality of pathological material not always adequate or quantity insufficient
  • Need for a system in place that would swiftly direct rare cancer patients to an expert centre together with appropriate data and good quality material

Research

  • Rare Cancer treatment not as attractive for the pharmaceutical industry (return on investment lower than for other cancers)
  • Randomised clinical trials considered not possible for rare cancers due to small numbers
  • Poor acceptance of adaptive designs and lower level evidence by regulators
  • Randomised clinical trials are feasible (except for ultra-rare cancers)
  • Need for large international collaboration
  • Need for incentives (funding)
  • Methodology concerns/Study design
  • Enrollment issues
  • Production issues (small quantities in each country)
  • Reimbursement issues
  • Paediatric specificity (long-term safety issues)
  • Post Marketing Authorisation issues

Patient participation in clinical trials

  • Cross-border participation in clinical trials
  • Patient involvement in the design of clinical trials
  • Better information of ongoing clinical trials and their results

European Reference Networks

  • Need to implement the ‘EU Directive on Patient’s Rights to Cross-border Healthcare’ (Directive 2011/24/EU) in order to allow prompt referral of rare cancer patients for timely and accurate diagnosis
  • Provisions for transfer of tissues
  • Need for processes to allow structured collaboration between specialists and centres of expertise at a national and European level
  • Establishment of cross-border networks of clinical databases and registries on rare cancers, with a focus on tissue banks, to foster translational and clinical research

Reimbursement

  • Of second opinion
  • Of innovative treatments (criteria should be different than for other cancers)
  • Of "off label" use of drugs

Patient consent

  • Informed consent needs to be more “patient friendly” (easy to understand wording)
  • Need for enduring (withdrawable) patient consent
  • Patients should be considered “experts” and their feedback taken into account

Centres of excellence

  • Need for Centres of Excellence where patients can be referred for second opinion and treatment
  • Provision for tele consultation and tele pathology
  • Centres should include tumour banks open to researchers

Download the complete Rare Cancers Europe Patient Advocacy Toolkit

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings